---
title: "MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274660684.md"
datetime: "2026-02-03T13:03:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274660684.md)
  - [en](https://longbridge.com/en/news/274660684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274660684.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274660684.md) | [繁體中文](https://longbridge.com/zh-HK/news/274660684.md)


# MeiraGTx Signs Exclusive License Agreement With ZipBio for Geographic Atrophy Gene Therapy

MeiraGTx Holdings plc has entered into an exclusive license agreement with ZipBio, a biotechnology company specializing in AI-driven protein therapeutics. Under the terms of the agreement, MeiraGTx will gain exclusive rights to develop and commercialize ZipBio’s first-in-class therapies for Geographic Atrophy, which target the complement pathway. The collaboration combines MeiraGTx’s expertise in genetic medicine development and manufacturing with ZipBio’s proprietary AI-based protein design platform, COMPACT™. The agreement includes upfront, milestone, and royalty payments, though specific financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via PR Newswire (Ref. ID: NY76566) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [TG Therapeutics, Inc. (TGTX.US)](https://longbridge.com/en/quote/TGTX.US.md)
- [MeiraGTx Holdings plc (MGTX.US)](https://longbridge.com/en/quote/MGTX.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/en/news/281390073.md)
- [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/en/news/280909399.md)
- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/en/news/281186075.md)
- [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)